Drug Profile
Samelisant - Suven Life Sciences
Alternative Names: SUVN-G3031Latest Information Update: 09 Nov 2023
Price :
$50
*
At a glance
- Originator Suven Life Sciences
- Class Acetamides; Antiparkinsonians; Cyclobutanes; Morpholines; Neuropsychotherapeutics; Nootropics; Phenyl ethers; Piperidines; Sleep disorder therapies; Small molecules
- Mechanism of Action Histamine H3 receptor inverse agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Narcolepsy
- No development reported Cognition disorders; Parkinson's disease
Most Recent Events
- 13 Jun 2023 Suven Life Sciences completes a phase II trial in Narcolepsy in USA, Canada (PO) (NCT04072380)
- 21 Sep 2022 Suven Life Sciences completes an expanded-access programme for Narcolepsy (NCT05530447)
- 07 Sep 2022 Suven Life Sciences initiates an expanded-access programme for Narcolepsy (NCT05530447)